Martin Investment Management Decreased Thermo Fisher Scientific (TMO) Stake By $396,144; Neogenomics Has 1.28 Sentiment

January 14, 2018 - By Hazel Jackson

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $667.40 million. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It currently has negative earnings. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.

Martin Investment Management Llc decreased Thermo Fisher Scientific Inc (TMO) stake by 2.87% reported in 2017Q3 SEC filing. Martin Investment Management Llc sold 2,096 shares as Thermo Fisher Scientific Inc (TMO)’s stock rose 8.13%. The Martin Investment Management Llc holds 70,855 shares with $13.41M value, down from 72,951 last quarter. Thermo Fisher Scientific Inc now has $84.28 billion valuation. The stock increased 0.72% or $1.51 during the last trading session, reaching $210.17. About 1.49M shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 15.57% since January 14, 2017 and is uptrending. It has underperformed by 1.13% the S&P500.

Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on February, 28. They expect $0.02 EPS, down 33.33% or $0.01 from last year’s $0.03 per share. NEO’s profit will be $1.61 million for 103.75 P/E if the $0.02 EPS becomes a reality. After $-0.02 actual EPS reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts -200.00% EPS growth.

General Electric Co holds 59.63% of its portfolio in NeoGenomics, Inc. for 15.00 million shares. First Light Asset Management Llc owns 2.41 million shares or 8.49% of their US portfolio. Moreover, Kopp Investment Advisors Llc has 4.63% invested in the company for 454,348 shares. The Wisconsin-based 1492 Capital Management Llc has invested 3.71% in the stock. Perkins Capital Management Inc, a Minnesota-based fund reported 308,300 shares.

The stock decreased 2.47% or $0.21 during the last trading session, reaching $8.3. About 469,360 shares traded or 36.39% up from the average. NeoGenomics, Inc. (NEO) has declined 13.46% since January 14, 2017 and is downtrending. It has underperformed by 30.16% the S&P500.

Ratings analysis reveals 100% of NeoGenomics’s analysts are positive. Out of 2 Wall Street analysts rating NeoGenomics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $11.0 while the high is $11.0. The stock’s average target of $11 is 32.53% above today’s ($8.3) share price. NEO was included in 2 notes of analysts from October 4, 2016. Cantor Fitzgerald initiated it with “Overweight” rating and $11.0 target in Thursday, December 15 report. The firm has “Overweight” rating by First Analysis given on Tuesday, October 4.

Among 18 analysts covering Thermo Fisher Scientific (NYSE:TMO), 17 have Buy rating, 0 Sell and 1 Hold. Therefore 94% are positive. Thermo Fisher Scientific had 53 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Friday, September 8 by Cowen & Co. Robert W. Baird maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Monday, October 2. Robert W. Baird has “Buy” rating and $194.0 target. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Outperform” rating given on Thursday, November 10 by Leerink Swann. Jefferies maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Tuesday, June 6. Jefferies has “Hold” rating and $17500 target. The company was maintained on Monday, January 11 by Stifel Nicolaus. The firm earned “Buy” rating on Wednesday, October 11 by Cowen & Co. As per Thursday, September 22, the company rating was initiated by JP Morgan. On Wednesday, October 25 the stock rating was maintained by Cowen & Co with “Buy”. On Thursday, July 20 the stock rating was upgraded by Cleveland to “Buy”. The company was downgraded on Friday, September 9 by Cleveland.

Analysts await Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings on January, 30. They expect $2.66 earnings per share, up 10.37% or $0.25 from last year’s $2.41 per share. TMO’s profit will be $1.07B for 19.75 P/E if the $2.66 EPS becomes a reality. After $2.31 actual earnings per share reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts 15.15% EPS growth.

Investors sentiment increased to 0.96 in Q3 2017. Its up 0.05, from 0.91 in 2017Q2. It improved, as 51 investors sold TMO shares while 383 reduced holdings. 77 funds opened positions while 339 raised stakes. 333.20 million shares or 3.09% more from 323.23 million shares in 2017Q2 were reported. Connable Office Incorporated invested in 0.77% or 19,877 shares. Montecito Financial Bank And has invested 0.19% in Thermo Fisher Scientific Inc. (NYSE:TMO). Moreover, Tiaa Cref Management Ltd Co has 0.17% invested in Thermo Fisher Scientific Inc. (NYSE:TMO). Wetherby Asset Mngmt has 6,378 shares for 0.18% of their portfolio. Sivik Global Ltd Limited Liability Company accumulated 2.9% or 45,000 shares. Utah Retirement, Utah-based fund reported 73,188 shares. Everence Management owns 11,235 shares. Rmb Cap Management Ltd Limited Liability Company accumulated 58,655 shares. Cohen Lawrence B reported 11,989 shares. 193,360 were accumulated by Cryder Ltd Liability Partnership. Boston Family Office Lc has 22,867 shares for 0.49% of their portfolio. Deutsche Bank Ag invested in 1.88M shares or 0.24% of the stock. Eaton Vance accumulated 498,047 shares. Public Employees Retirement Association Of Colorado owns 400,386 shares for 0.55% of their portfolio. S&Co invested 1.19% in Thermo Fisher Scientific Inc. (NYSE:TMO).

Since August 2, 2017, it had 0 insider purchases, and 7 insider sales for $18.71 million activity. 4,140 shares valued at $736,092 were sold by HOOGASIAN SETH H on Monday, August 28. Herrema Gregory J. sold $5.28M worth of stock or 30,000 shares. $9.59 million worth of Thermo Fisher Scientific Inc. (NYSE:TMO) shares were sold by CASPER MARC N. Shine Daniel P had sold 2,026 shares worth $366,645. Shares for $721,091 were sold by HORNSTRA PETER E on Tuesday, September 5. MANZI JIM P had sold 11,318 shares worth $1.96M. 360 shares were sold by HARRIS C MARTIN, worth $65,149 on Wednesday, August 30.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>